Efficacy and Safety of Dupilumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

The document from May 2019 detailed a study on the use of dupilumab (DPL) for treating adolescents with moderate-to-severe atopic dermatitis (AD). The study included a phase 2a trial with 40 participants aged 12 to less than 18 years, and a phase 3 open-label extension trial with 36 patients. The primary outcomes were the drug's concentration-time profile and the rate of adverse events (AEs), while secondary outcomes focused on improvements in dermatitis severity and itchiness. The results indicated that DPL was well tolerated, with nasopharyngitis being the most common AE and no discontinuations due to AEs. There were significant improvements in dermatitis severity and itchiness, with many patients achieving a more than 75% reduction in severity and a clear or almost clear skin rating at Week 12 and Week 52. The study concluded that DPL is beneficial and safe for adolescents with AD, similar to the adult population, and recommended further research in this age group.